Brought to you by 
Merck & SmithKline Beecham co-promote Zocor
13 Jul 1999
Executive Summary
Merck and SmithKline Beecham will co-promote Zocor, a newly-approved Merck drug which lowers cholesterol, in the US. In return, Merck will have future co-promotion rights to an unnamed SmithKline Beecham product (rumored to be Seroxat.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
- Product or Technology Swap
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck & SmithKline Beecham co-promote Zocor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice